Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT)

•In chronic myeloid leukemia (CML) patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HCT) from an unrelated donor (UD), post-transplantation cyclophosphamide (PTCy) or a mainly calcineurin inhibitor-based graft-versus-host disease prophylaxis were associated with similar graft-versus-host disease/ relapse-free survival, overall survival, nonrelapse mortality, progression-free survival, and RI.•PTCy UDs and PTCy mismatched related donors are feasible allo-HCT platforms in CML patients.•Patient age, disease status, and Karnofsky Performance Status remain strong prognostic factors for survival in allo-HCT for CML, highlighting the important of performing allo-HCT when indicated.